The planned merger between Tabcorp and Tatts Group is in danger of collapsing after the Australian Competition and Consumer Commission formally opposed the deal.
In October last year, Tabcorp and Tatts unveiled plans to join forces in a deal that would lead to the creation of a combined business worth approximately €7.3bn/US$8.2bn.
However, according to The Australian newspaper, Andrew McClelland QC, counsel for the country’s competition watchdog, denied Tabcorp claims in the Australian Competition Tribunal that the merger would be of significant public benefit, adding that cost savings set out were “inherently implausible” and “speculative”.
McClelland added: “Although Tabcorp has asserted that some of these cost savings and revenue increases will flow through to the community, the majority of the claimed synergies are proposed to be retained by Tabcorp and should be given little weight.”
The ACCC also picked up on competition concerns that were raised earlier this year, although Tabcorp previously announced plans to sell its Odyssey gaming machine monitoring business to ease any worries.
“The competitive constraint Tabcorp and Tatts impose on each other will be lost with the proposed acquisition and will likely give Tabcorp the ability to increase yields,” McClelland said.
Full Content: Gambling Insider
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan